Merz Pharma Outbids Valeant for Obagi

Oops. Did we say that "Montreal-based Valeant Pharmaceuticals (NYSE: VRX  ) is buying Long Beach, Calif.-based specialty pharma company Obagi Medical Products (UNKNOWN: OMPI.DL  ) for about $344 million" -- a price of only 2.9 times sales, versus Valeant's own 6.2 P/S ratio?

What we meant to say was that Valeant was hoping it could get the shares at such a nice discount. Turns out, though, that someone else is willing to bid quite a bit more for Obagi. That someone emerged this morning, when Germany's Merz Pharmaceuticals sent Obagi's board a letter offering to buy the same stock for 11% more -- $22 a share.

Merz calls its offer a "superior proposal" to the one Valeant tendered last month. Merz says it's also ready to buy right away, needs to perform no additional due diligence, and has the cash in hand to make the buy "immediately" -- all of which has to make this a very tempting offer for Obagi.

For its part Obagi's board confirmed this morning that it's received Merz's offer and will "evaluate" it with the understanding that "time is of the essence." Expect a reply soon.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2342625, ~/Articles/ArticleHandler.aspx, 12/22/2014 5:47:10 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement